Bibliographic Info
GuidelineConsolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations
Year of Publication2016
Issuing InstitutionWHO
Recommendation
Status
Maintained
Recommended in favor
Strong
Certainty of evidence
Low
People from key populations with HIV and HBV coinfection who have severe chronic liver disease should be offered ART with a tenofovir (TDF) and lamivudine (3TC) (or emtricitabine (FTC))-based regimen irrespective of CD4 count or WHO clinical stage
Notes and Remarks
- 1)New WHO clinical guidance on hepatitis B treatment and screening strategies for hepatitis B and C, have been developed in 2014 and 2015.
- 2)WHO HCV guidelines provide detailed guidance on treatment and care (158).
- 3)There are challenges in diagnosing and treating active HCV infection in certain populations such as people who inject drugs, particularly in settings with limited access to HCV antibody and RNA assays, diagnostic tools for staging of liver disease and HCV therapy. People receiving ART and HCV drugs require close monitoring for possible drug interactions
Also Featured In
This recommendation also appears in the following guidelines:
Originally Developed
Guideline
Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations
Year2014
InstitutionWHO
Guideline
Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection
Year2015
InstitutionWorld Health Organization